000			nab a22 7a 4500
999			_c16847 _d16847
003			PC16847
005			20220512121603.0
008			220512b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91488 _aPraga Terente, Manuel _eNefrología
100			_9285 _aSevillano Prieto, Ángel Manuel _eNefrología
100			_92305 _aAuñón Rubio, Pilar _eNefrología
100			_93038 _aGonzález, Ester _eNefrología
245	0	0	_aChanges in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. _h[revisión]
260			_bNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, _c2015
300			_a30(9):1472-9.
500			_aFormato Vancouver: Praga M, Sevillano A, Auñón P, González E. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015 Sep;30(9):1472-9.
501			_a PMID: 25324356
504			_aContiene 72 referencias
520			_aAcute interstitial nephritis (AIN) is an important cause of acute kidney injury that has experienced significant epidemiological and clinical changes in the last years. The classical presentation, mostly induced by antibiotics and accompanied by evident hypersensitivity manifestations (skin rash, eosinophilia, fever) has been largely replaced by oligosymptomatic presentations that require a higher index of suspicion and are increasingly recognized in the elderly, having non-steroidal anti-inflammatory agents and proton pump inhibitors as frequent offending drugs. Drug-induced AIN continues to be the commonest type, but it requires a careful differential diagnosis with other entities (tubulointerstitial nephritis with uveitis syndrome, IgG4-related disease, drug reaction with eosinophilia and systemic symptom syndrome, sarcoidosis and other systemic diseases) that can also induce AIN. Cortico-dependant, relapsing AIN is a recently recognized entity that poses an important therapeutic challenge. Although corticosteroids are widely used in drug-induced AIN to speed kidney function recovery and avoid chronic kidney disease, their efficacy has not been tested by randomized controlled trials. New diagnostic tests and biomarkers, as well as prospective therapeutic studies are needed to improve AIN diagnosis and management.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16847.pdf _ySolicitar documento
942			_2ddc _cREV _n0